Fujisawa Pharmaceutical Company, Ltd.

Masami Ezaki

Masakuni Okuhara

Shigehiro Takase

Seiji Hashimoto

Nobuharu Shigematsu

Eisaku Tsujii

Miho Tanaka

Satoshi Ueda

Michio Yamashita

Masaru Tsuboi

Kazutoshi Sakamoto

Nobutaka Oohata

Hiroshi Hatanaka

Masanori Okamoto

Satoshi Okada

Masanobu Kohsaka

Tohru Kino

Tadaaki Komori

Sumio Kiyoto

Motoaki Nishikawa

Michiyo Miyauchi

Toshio Goto

Yasuhisa Tsurumi

Morita Iwami

Yasuhiro Hori

Kazuyoshi Umehara

Motohiro Hino

Kozo Ochi

Hideo Hirai

Akira Katayama

Kunio Nakahara

Hidenori Nakajima

Yoshitada Notsu

Yasuhiko Shinguh

Noriaki Inamura

Cyclic lipopeptide acylase

Process for the deacylation of cyclic lipopeptides

The present invention provides a new bioactive compound of formula (I), which has an antimicrobial activity against pathogenic microorganisms, and a process for production thereof. Also provided are a pharmaceutical composition comprising the compound and pharmaceutically acceptable carrier, a use of the WF002 as a medicament and use of the compound for manufacture of the medicament for treatment of infectious disease.

Compound, WF002, production thereof and use thereof

There is provided a cyclic lipopeptide acylase which is capable of deacylating the acyl side chain of a cyclic lipopeptide compound, e.g. Substance FR901379 or its analog, of the general formula &lsqb;I&rsqb; with effectiveness as well a method of producing a cyclic peptide compound which comprises using the acylase.

A method of killing pathogenic fungi by contacting them with an effective amount of (1R,2S)-2-aminocyclopentanecarboxylic acid (FR109615) or a salt thereof.

Antimicrobial agent, FR109615 and production thereof

The novel peptides WS-9326A, WS-9326B, their derivatives and pharmaceutically acceptable salts thereof have useful pharmacological activities, particularly in the treatment and/or prevention of asthma and/or pain. A method for the production of the peptides WS-9326A and WS-9326B and derivatives thereof using Streptomyces violaceoniger No. 9326 in a biologically pure form is described herein.

Process for producing WS-9326A and WS-9326B

A degenerative disease selected from the group consisting of cystic fibrosis, chronic bronchitis and bronchiectasia is treated by administering to a subject a therapeutically effective amount of WS7622A mono-or disulfate or pharmaceutically acceptable salt thereof.

WS7622A mono- or di-sulfate, process for preparation thereof and use

WS7622A mono- or di-sulfate and pharmaceutically acceptable salts thereof. WS7622A exhibits human leukocyte elastase-inhibiting activity.

WS7622A mono- or di- sulfate, process for preparation thereof and use

A method for therapy of disseminated intravascular coagulation, or chronic respiratory tract infectious disease characterized by administering to a patient in need thereof an effective dose suitable for therapeutic treatment of said condition of WS7622A mono- or di-sulfate ester or their pharmaceutically acceptable salt.

Prophylactic/therapeutic composition for disseminated intravascular

This invention relates to the novel peptides WS-9326A, WS-9326B, their derivatives and pharmaceutically acceptable salts thereof which have pharmacological activities, particularly in the treatment and/or prevention of asthma and/or pain.

Peptides WS-9326a and WS-9326b, derivatives thereof and uses thereof

A method of treating pulmonary emphysema or adult respiratory distress syndrome in a subject in need thereof which comprises administering to the subject an effective amount of WS7622A, B, C and/or D, derivatives thereof, or their pharmaceutically acceptable salt.

WS7622A, B, C and D substances, derivatives thereof, processes for

(1R, 2S)-2-Aminocyclopentanecarboxylic acid and its salts useful as antimicrobial agents.

Growing community of inventors

Tsukuba, Japan

Masami Ezaki